Bailard’s Aligos Therapeutics ALGS Stock Holding History

Bailard’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-776	Closed	-$21K	–	704
2022 Q3	$21K	Buy	+776	New	+$25.8K	﹤0.01%	659

Other funds holding ALGS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bailard's ALGS Position: Q4 2022 in Review

Bailard sold out of Aligos Therapeutics (ALGS) in Q4 2022, closing a stake of 776 shares — an estimated $21K sold.

Bailard first reported a position in ALGS in Q3 2022 and held it in 1 quarter. The position peaked at $21K in Q3 2022. 38 funds tracked by Wall St. Rank hold ALGS as of Q4 2022.

Bailard reported no remaining Aligos Therapeutics position as of Q4 2022 after selling out during the quarter.
Bailard sold 776 Aligos Therapeutics shares in Q4 2022, an estimated $21K.
Bailard first reported a position in Aligos Therapeutics in Q3 2022 and held it in 1 quarter.
Bailard's Aligos Therapeutics position peaked at $21K in Q3 2022.
38 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2022.

Based on Bailard's 13F filing for Q4 2022, filed 2 Feb 2023.